PARP inhibitors are a class of therapeutic agents that have been shown to be effective for the treatment of malignancies, including tumours associated with BRCA1/2 mutations or without BRCA mutations but with homologous recombination deficiencies [3–5]. The gene discussed is BRCA1; the disease is neoplasm.